Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission
A recently published study of 190 RA patients, who were in sustained remission (DAS28-CRP≤2.6) and no radiographic progression the previous year showed that Doppler Ultrasound can predict successful discontinuation of biological DMARDs. Doppler sum score was an independent predictor for successful discontinuation of biological disease-modifying anti-rheumatic drugs (bDMARDs) at 2-year follow-up – the odds for achieving successful discontinuation decreased by 56% per one-unit increase in Doppler sum score. The authors note that Ultrasound could not predict successful tapering.
The paper published in Rheumatology (Oxford), is a successful collaboration between a number of academic institutions and radiology experts. It is critical for patient care and successful assessment of treatment impact to find correlation between imaging and clinical outcomes as well as to tap into the imaging biomarker predictive power.
Title: Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission
Journal: Rheumatology (Oxford), 2021 Mar 20
Authors: Lene Terslev, Cecilie Heegaard Brahe, Merete Lund Hetland, Stylianos Georgiadis, Karen Ellegaard, Lars Juul, Tuan Huynh, Uffe Møller Døhn, Viktoria Fana, Torsten Møller, Simon Krabbe, Lykke Midtbøll Ørnbjerg, Daniel Glinatsi, Henrik Røgind, Anette Hansen, Jesper Nørregaard, Søren Jacobsen, Dorte Vendelbo Jensen, Natalia Manilo, Karsten Asmussen, Mikael Boesen, Zoreh Rastiemadabadi, Lone Morsel-Carlsen, Jakob Møllenbach Møller, Niels Steen Krogh, Mikkel Østergaard
Access Online: https://doi.org/10.1093/rheumatology/keab276
Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes.
Reach out to our expert team to discuss your development programs: email@example.com